Abstract
Background NVX-CoV2373 (Nuvaxovid™ or the Novavax COVID-19 Vaccine, Adjuvanted), the first protein-based COVID-19 vaccine, received emergency use authorization (EUA) as a primary series/booster and is available globally. NVX-CoV2373 primary series demonstrated efficacy rates of 89·7–90·4 % and an acceptable safety profile. This article summarizes safety in adult recipients (aged ≥18 years) of primary series NVX-CoV2373 in four randomized placebo-controlled trials.
Methods All participants who received NVX-CoV2373 primary series or placebo (pre-crossover) were included according to actual received treatment. The safety period was from Day 0 (first vaccination) to unblinding/receipt of EUA-approved/crossover vaccine, end of each study (EOS), or last visit date/cutoff date minus 14 days. The analysis reviewed local and systemic solicited adverse events (AEs) within 7 days after NVX-CoV2373 or placebo; unsolicited AEs from after Dose 1 to 28 days after Dose 2; serious AEs (SAEs), deaths, AEs of special interest, and vaccine-related medically attended AEs from Day 0 through end of follow-up (incidence rate per 100 person-years).
Findings Pooled data from 49,950 participants (NVX-CoV2373, n=30,058; placebo, n=19,892) were included. Solicited reactions after any dose were more frequent in NVX-CoV2373 recipients (local, 76%/systemic, 70%) than placebo recipients (29%/47%), and were mostly of mild-to-moderate severity. Grade 3+ reactions were infrequent, with greater frequency in NVX-CoV2373 recipients (6·28%/11·36%) than placebo recipients (0·48%/3·58%). SAEs and deaths occurred with similarly low frequency in NVX-CoV2373 (0·91% and 0·07%, respectively) and placebo recipients (1·0% and 0·06%).
Interpretation To date, NVX-CoV2373 has displayed an acceptable safety profile in healthy adults.
Funding Supported by Novavax, Inc.
Competing Interest Statement
All authors are employees and shareholders of Novavax, Inc.
Clinical Trial
This manuscript summarizes four randomized placebo-controlled trials: the phase 1/2 2019nCoV-101 study (NCT04368988), the phase 3 2019nCoV-301 study (NCT04611802), the phase 3 2019nCoV-302 study (EudraCT number, 2020-004123-16), and the phase 2A/2B 2019nCoV-501 study (NCT04533399).
Funding Statement
This work was funded by Novavax, Inc., and the sponsor had primary responsibility for study design, study vaccines, protocol development, study monitoring, data management, and statistical analyses. This manuscript summarizes four randomized placebo-controlled trials. The phase 1/2 2019nCoV-101 study (NCT04368988) was supported by the Coalition for Epidemic Preparedness Innovations. The phase 3 2019nCoV-301 study (NCT04611802) was supported by the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health. The phase 3 2019nCoV-302 study (EudraCT number, 2020-004123-16) was supported by Novavax, Inc. The phase 2A/2B 2019nCoV-501 study (NCT04533399) was supported by Novavax, Inc. and the Bill and Melinda Gates Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
302 Study: The trial protocol was approved by the North West-Greater Manchester Central 16 Research Ethics Committee (Ref 20/NW/03/99) 301 study: The following Institutional Review Boards / Independent Ethics committees reviewed and approved the study: -Western Copernicus Group IRB, US; Great Plains IRB, US; Comite de etica en investigacion del Instituto Nacional de Ciencias Medicas y Nutricion, Salvador Zubiran, Mexico; Comite de etica en investigacion de la Unidad de Atencion Medica e Investigacion en Salud S.C., Mexico; Comite de etica en investigacion del Instituto Nacional de Salud Publica, Mexico; Comite de etica en investigacion de Medica Rio Mayo S.C., Mexico; Comite de etica en investigacion del Hospital La Mision S.A. de C.V., Mexico. 101 study: The trial protocol was approved by the Alfred Hospital Human Research Ethics Committee (Melbourne, Australia) and Advarra Central Institutional Review Board (Columbia, Maryland, USA) 501 study: The protocol was approved by the South African Health Products Regulatory Authority and by the institutional review board at each trial center.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The trial protocols and statistical analysis plans will be made available upon publishing of the manuscript by request to the corresponding author. Additional information is available at clinicaltrials.gov.
